Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q2 2022 · 10-Q
Revenue$559.36M$559.36M+4.5% vs Q2 2021 Net Income-$242.13M-$242.13MN/M vs Q2 2021 EPS Diluted-$0.80-$0.80N/M vs Q2 2021 Gross Profit$200,519,000−5.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flowderived-$125,521,000N/M Free Cash Flowderived-$130,570,000N/M Margins · derivedGross margin35.8%−3.9 pt vs Q2 2021
Operating margin-35.5%−48.1 pt vs Q2 2021
Net margin-43.3%−48.9 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 8, 2022 · 39 d after period end